

# Transcranial random noise stimulation for the acute treatment of depression: a randomized controlled trial

Stevan Nikolin<sup>1,2</sup>, Angelo Alonzo<sup>1,2</sup>, Donel Martin<sup>1,2</sup>, Veronica Gálvez<sup>1,3</sup>, Sara Buten<sup>1,4</sup>,  
Rohan Taylor<sup>1,5</sup>, James Goldstein<sup>6</sup>, Cristal Oxley<sup>7</sup>, Dusan Hadzi-Pavlovic<sup>1</sup>, Colleen K.  
Loo<sup>1,2,8</sup>

<sup>1</sup> School of Psychiatry, University of New South Wales, Sydney, Australia

<sup>2</sup> Black Dog Institute, Sydney, Australia

<sup>3</sup> Mental Health Department, Parc Taulí University Hospital, Institut d'Investigació I  
Innovació Sanitària Parc Taulí (I3PT), Barcelona, Spain

<sup>4</sup> Prince of Wales Hospital, Sydney, Australia

<sup>5</sup> Concord Centre for Mental Health, Concord, Australia

<sup>6</sup> Currumbin Clinic, Currumbin, Australia

<sup>7</sup> Department of Child and Adolescent Psychiatry, Michael Rutter Centre – South London and  
Maudsley NHS Foundation Trust, UK

<sup>8</sup> St. George Hospital, Sydney, Australia

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 18 **Abstract**

### 19 **Background**

20 Transcranial electrical stimulation has broad potential as a treatment for depression.  
21 Transcranial random noise stimulation (tRNS), which delivers randomly fluctuating current  
22 intensities, may have greater cortical excitatory effects compared to other forms of  
23 transcranial electrical stimulation. We therefore aimed to investigate the antidepressant  
24 efficacy of tRNS.

### 25 **Methods**

26 Depressed participants were randomly assigned by computer number generator to receive 20  
27 sessions of either active or sham tRNS over four weeks in a double-blinded, parallel group  
28 randomized-controlled trial. tRNS was delivered for 30mins with a direct current offset of  
29 2mA and a random noise range of 2mA. Primary analyses assessed changes in depression  
30 severity using the Montgomery-Asperg Depression Rating Scale (MADRS). Neuroplasticity,  
31 neuropsychological, and safety outcomes were analysed as secondary measures.

### 32 **Results**

33 69 participants were randomised, of which three discontinued treatment early leaving 66  
34 (sham n = 34, active n = 32) for per-protocol analysis. Depression severity scores reduced in  
35 both groups (MADRS reduction in sham = 7.0 [95%CI 5.0-8.9]; and active = 5.2 [95%CI  
36 3.2-7.3]). However, there were no differences between active and sham groups in the  
37 reduction of depressive symptoms, or the number of participants meeting response (sham =  
38 14.7%; active = 3.1%) and remission criteria (sham = 5.9%; active = 0%). Erythema,  
39 paraesthesia, fatigue, and dizziness/light-headedness occurred more frequently in the active  
40 tRNS group. Neuroplasticity, neuropsychological and acute cognitive effects were  
41 comparable between groups.

42 **Conclusion**

43 Our results do not support the use of tRNS with the current stimulation parameters as a  
44 therapeutic intervention for the treatment of depression.

45 **Clinical Trial Registration:**

46 Clinical registration was obtained on the 15<sup>th</sup> February 2013 from [clinicaltrials.gov](http://clinicaltrials.gov)  
47 (NCT01792414) after recruitment of the first study participant on the 30<sup>th</sup> January 2013, but  
48 prior to the participant's completion of the four week sham-controlled phase of the trial. All  
49 remaining participants were recruited following clinical registration.

50 **Funding:** NHMRC project grant APP1051423

51

52 **Keywords:**

- 53 • Transcranial Random Noise Stimulation
- 54 • Electric Stimulation Therapy [E02.331]
- 55 • Depression [F01.145.126.350]
- 56 • Randomized Controlled Trial [V03.175.250.500.500]

## 57 Introduction

58           Although there are a number of established treatments for depression, a sizeable  
59 proportion of patients still fail to adequately respond, with a conservative estimate of  
60 approximately one-third of these not reaching remission even after four trials of different  
61 antidepressant medication classes (Rush et al., 2006). In addition, many patients fail to  
62 complete a course of antidepressants due to side effects (Trivedi et al., 2006). While  
63 electroconvulsive therapy (ECT) remains the most effective treatment, with response rates of  
64 up to 70% (Haq et al., 2015), treatment uptake and adherence can be limited by patient  
65 concerns over possible cognitive side effects and the need for general anaesthetic. Thus, there  
66 has been interest in the development of novel, non-convulsive brain stimulation techniques  
67 that are well-tolerated and have a benign side effect profile, such as transcranial electrical  
68 stimulation. These neuromodulatory techniques could have the greatest potential for  
69 translation into widespread clinical use, being relatively inexpensive, easy to use, portable,  
70 and safe (Bikson et al., 2016; Nikolov et al., 2017). Here we report an investigation of the  
71 efficacy of one such technique, transcranial random noise stimulation (tRNS), for the  
72 treatment of depression.

73           Transcranial electrical stimulation involves applying a weak electrical current to  
74 cerebral tissue via scalp electrodes, resulting in modulation of neuronal membrane potentials  
75 and spontaneous firing rates (Nitsche et al., 2008) that can lead to long term changes in  
76 cortical excitability and plasticity (Nitsche and Paulus, 2001; Player et al., 2014a). Applying  
77 a direct current between the electrodes, referred to as transcranial direct current stimulation  
78 (tDCS), has been demonstrated to have antidepressant effects in clinical trials (Loo et al.,  
79 2012a; Brunoni et al., 2013b; Brunoni et al., 2017). Recent meta-analyses of randomised,  
80 sham-controlled trials have found tDCS to be more effective than sham stimulation, with

81 significantly higher remission and response rates as well as a greater reduction in depressive  
82 symptoms (Brunoni et al., 2016; Mutz et al., 2018). As depression has increasingly been  
83 conceptualised as a disorder underpinned by disrupted neuroplasticity (Pittenger and Duman,  
84 2008; Liu et al., 2017), cumulative changes to synaptic functioning may underlie the  
85 therapeutic effects observed in clinical trials of tDCS (Szymkowicz et al., 2016). Modifying  
86 stimulation parameters to enhance cortical excitability effects may therefore present a  
87 pathway to increase treatment efficacy.

88 tRNS is a more recently developed transcranial electrical stimulation technique that  
89 involves randomly fluctuating current intensities over a broad frequency spectrum (between  
90 0.1 to 640 Hz). There is some evidence that tRNS has comparable, if not greater, cortical  
91 excitatory effects as compared to tDCS (Moliadze et al., 2014; Ho et al., 2015b; Inukai et al.,  
92 2016). A single session of 10 minutes of 1 milliampere (mA) tRNS to the motor cortex has  
93 been found to produce a greater increase in cortical excitability than tDCS, lasting up to 60  
94 minutes beyond the stimulation period (Moliadze et al., 2014; Inukai et al., 2016), although  
95 tDCS may lead to a longer period of excitation of at least 90 minutes post-stimulation  
96 (Moliadze et al., 2014). tRNS may also be applied with a direct current offset so that the  
97 stimulation incorporates neuromodulatory features of tDCS, in addition to limiting  
98 homeostatic responses via randomly fluctuating current intensities. Results from Ho et al.  
99 (2015b) suggest that tRNS with a direct current offset may be more effective in increasing  
100 motor cortical excitability than the more common application of tRNS without an offset.

101 There has been a burgeoning growth in recent years of studies investigating the  
102 application of tRNS to enhance sensory processing (Ghin et al., 2018; Rufener et al., 2018;  
103 Contemori et al., 2019), motor performance (Abe et al., 2019; Jooss et al., 2019), and  
104 cognition (Snowball et al., 2013; Popescu et al., 2016; Mammarella et al., 2017; Shalev et al.,  
105 2018; Tyler et al., 2018) in healthy participants with largely promising results. To date,

106 however, few studies have examined the effectiveness of tRNS for clinical/therapeutic uses,  
107 with such studies typically characterised by small sample sizes and/or varying efficacy (Chan  
108 et al., 2012; Haesebaert et al., 2014; Palm et al., 2016a; Hayward et al., 2017; Kreuzer et al.,  
109 2017; Salemi et al., 2019). Regarding the effects of tRNS on mood, there is currently only  
110 one report involving treatment of major depressive disorder (MDD). Chan et al. (2012)  
111 reported a case of a patient diagnosed with MDD who had responded to two trials of tDCS (2  
112 mA, 20 minutes, 15 sessions over 3 weeks) prior to trialling a 4-week course of open-label  
113 tRNS (2 mA range with 1 mA direct current offset, 20 sessions lasting 20 minutes each). It  
114 was found that by the 15<sup>th</sup> session, there was a 63% reduction from baseline in the severity of  
115 depressive symptoms, compared with a reduction of 31% and 25% at the end of the acute  
116 treatment phase in the two prior trials of tDCS. For all three trials, depression scores at  
117 baseline were similar but the patient reported faster improvement with tRNS and lesser skin  
118 sensations compared to tDCS. Given this encouraging case report finding, and the potential  
119 theoretical advantages of tRNS relative to tDCS, further investigation of the antidepressant  
120 effects of tRNS is warranted.

121 The primary aim of this study, therefore, was to conduct the first randomised, sham-  
122 controlled trial of tRNS in depression. It was hypothesised that tRNS would have significant  
123 antidepressant efficacy compared with a sham control over a 4-week treatment phase. A  
124 secondary aim of this study was to examine whether antidepressant effects of tRNS were  
125 mediated by restoration of brain neuroplasticity. We hypothesised that antidepressant  
126 response to tRNS would be associated with increased brain plasticity, given prior findings of  
127 reduced neuroplasticity in depressed individuals compared to healthy matched controls  
128 (Player et al., 2013), and findings suggesting a normalisation of neuroplasticity following  
129 antidepressant treatment using tDCS (Player et al., 2014b). Lastly, as this is the first treatment  
130 trial of tRNS for depression, a comprehensive neuropsychological test battery was designed

131 specifically to be sensitive to symptom changes, measure any adverse cognitive effects, and  
132 to assess any potential acute cognitive enhancing effects.

## 133 **Materials and Methods**

### 134 **Trial design**

135 The main study phase used a double-blinded, parallel, randomized, sham-controlled  
136 design. Participants were assigned by a computer-generated random number sequence to one  
137 of two groups: active tRNS or sham tRNS. Randomization was stratified according to  
138 whether participants were diagnosed with unipolar or bipolar depression. Participants were  
139 required to attend a total of 20 tRNS sessions over four weeks conducted on consecutive  
140 weekdays during the sham-controlled phase. Participants who missed five or more sessions  
141 during the sham-controlled phase were withdrawn from the trial, and were excluded from  
142 analyses using a per-protocol approach. All participants were offered an additional 20  
143 sessions of open-label active tRNS over four weeks, also administered every weekday. After  
144 treatment in the acute daily treatment phases, participants entered a taper phase during which  
145 they received once weekly tRNS treatment for four weeks with the final taper session  
146 coinciding with a 1-month follow-up visit. Participants were then followed up at 3, 6 and 9  
147 months. Participants and raters were blinded to tRNS condition and blinding was maintained  
148 until the study was completed and the dataset locked.

149 Mood, neuroplasticity, and neuropsychological function were assessed at the intervals  
150 shown in Supplementary Table S1. Adequacy of blinding to treatment was assessed at the end  
151 of the sham-controlled phase by asking participants and raters to guess the tRNS condition  
152 administered during the first four weeks of treatment. To investigate whether treatment  
153 expectations may be a predictor of response, participants completed the Treatment

154 Expectancy Questionnaire (TEQ; see Supplementary Figure S1) at baseline before the first  
155 tRNS session.

156 The study was powered for the primary aim of testing efficacy over the sham-  
157 controlled phase. From pilot data, it was assumed that tRNS would be at least as effective as  
158 tDCS when tested in a sham-controlled trial, given that sampling criteria were very similar.  
159 Means and standard deviations of the active and sham treatment groups from our previous,  
160 sham-controlled, 3-week trial of tDCS (Loo et al., 2012b) were used, with outcomes  
161 extrapolated for a 4-week comparison period. This resulted in an effect size of Cohen's  $d =$   
162 0.7. For 80% power and  $\alpha = 0.05$ , a sample of 33 subjects per group was required to  
163 demonstrate a difference between active and sham treatment.

164

## 165 **Participants**

166 At study entry, participants were at least 18 years old; in a current major depressive  
167 episode (as part of a MDD or Bipolar Disorder) of a minimum four weeks duration, defined  
168 according to Diagnostic and Statistical Manual of Mental Disorders (fourth edition, text  
169 revision; DSM-IV-TR) criteria and established using the Mini International Neuropsychiatric  
170 Interview (MINI; Version 5.0.0) (Sheehan et al., 1998) and study clinician assessment; and  
171 had a total score of at least 20 on the Montgomery-Asberg Depression Rating Scale  
172 (MADRS) (Montgomery and Asberg, 1979). Participants were free of antidepressant  
173 medications, or continued on stable doses of antidepressant medications to which they had  
174 failed to respond after an adequate course of treatment, with dosage unchanged for at least  
175 four weeks prior to study entry. Bipolar participants were required to be on a mood stabilizer  
176 medication (e.g. lithium) as prophylaxis against treatment-emergent mania or hypomania for  
177 the duration of the study.



178 Exclusion criteria included: psychotic disorder as per DSM-IV-TR; drug or alcohol  
179 abuse or dependence within 12 months of study entry; inadequate response to ECT in the  
180 current depressive episode; current benzodiazepine medication; rapid clinical response  
181 required (e.g., due to high suicide risk); clinically defined neurological disorder or insult;  
182 metal in the cranium; skull defects; skin lesions on the scalp at electrode sites; or pregnancy.

183 The study was approved by the human research ethics committee of the University of  
184 New South Wales and was conducted at the Black Dog Institute in Sydney, Australia.  
185 Participants provided written informed consent for this study. Recruitment began in January  
186 2013 and the last follow-up was conducted in 2017. The study was registered with the  
187 ClinicalTrials.gov website (Identifier: NCT01792414).

188

### 189 [Transcranial random noise stimulation](#)

190 A DC-Stimulator Plus device (NeuroConn GmbH, Germany) applied high frequency  
191 tRNS (100-640 Hz) via two 7 x 5 cm saline-soaked sponge-covered electrodes held in  
192 position by a headband. Active tRNS was administered for 30 mins per session with a range  
193 of 2 mA and an offset of 2 mA. The anode was placed over F3 (as per the 10-20 international  
194 electroencephalogram system), corresponding to the left dorsolateral prefrontal cortex  
195 (LDLPFC), and the cathode over F8. For sham stimulation, the current was ramped up over  
196 10 s, left on for 30 s, then gradually ramped down over 10 s, so that both treatment groups  
197 experienced an initial tingling sensation. The tRNS machine was then left on until the end of  
198 the session to preserve blinding. This sham procedure resulted in adequate blinding for tDCS  
199 in previous trials (e.g., (Loo et al., 2010; Loo et al., 2012b)), and was therefore expected to be  
200 sufficient for tRNS, which produces milder skin sensations compared to tDCS (Ambrus et al.,  
201 2010). Participants were comfortably seated at rest and did not engage in any particular tasks  
202 during stimulation.

203

## 204 Clinical outcome measures

205 The primary outcome measure for comparing active and sham tRNS was the MADRS,  
206 which was administered by trained raters with established inter-rater reliability (intraclass  
207 correlation coefficient > 0.7). Secondary measures were the Clinician Global Impression –  
208 Improvement (CGI-I) (Guy, 1976), Beck Depression Inventory (BDI-II) (Beck et al., 1996) and  
209 Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form (Q-LES-SF)  
210 (Endicott et al., 1993) scales.

211

## 212 Neuroplasticity outcome measures

213 As an optional study offered to participants in the main tRNS trial, a paired  
214 associative stimulation (PAS) paradigm previously described in Player et al. (2012) was used  
215 to assess the effects of tRNS on neuroplasticity. The PAS testing was conducted at baseline  
216 before the first tRNS session, and again after completion of the sham-controlled and open-  
217 label phases. Briefly, the PAS paradigm involves measuring motor evoked potentials (MEPs)  
218 following single-pulse transcranial magnetic stimulation (TMS) via electromyography  
219 (EMG) before and after applying a stimulation protocol (i.e., PAS) to the motor cortex to  
220 assess changes in motor cortical excitability (see the Supplementary Material for a detailed  
221 description of PAS methodology).

222

## 223 Neuropsychological outcome measures

224 The following neuropsychological battery was administered to comprehensively  
225 assess cognitive function: California Verbal Learning Test-II (CVLT-II) (Delis et al., 2000) –  
226 verbal learning and memory; Ruff 2 & 7 (Ruff and Allen, 1996) – attention processes;  
227 Wechsler Adult Intelligence Scale-IV edition (WAIS-IV) Digit Span subtest (Wechsler,

228 2008) – simple auditory attention and working memory; Symbol Digit Modality Test  
229 (SDMT) (Smith, 1991) – psychomotor processing speed; Delis-Kaplan Executive Function  
230 System (D-KEFS) Verbal Fluency test (Delis et al., 2001) – phonemic fluency, semantic  
231 fluency, cognitive flexibility; and Cognitive Failures Questionnaire (Broadbent et al., 1982) –  
232 subjective cognitive functioning. Alternative versions of the CVLT-II, D-KEFS Verbal  
233 Fluency, and SDMT were used to minimize practice effects. In addition, computer  
234 administered cognitive tests were used to assess safety and acute effects. A simple reaction  
235 time test, in which participants were instructed to press a space bar as soon as they saw a  
236 cross appear in the middle of a computer screen, was administered immediately before and  
237 after the first tRNS session. An Emotion Recognition Task (Montagne et al., 2007), which  
238 assessed recognition of six basic facial emotions, was also administered after the first tRNS  
239 session.

240

#### 241 **Physical adverse events**

242 As an additional safety outcome measure, physical adverse events were assessed each  
243 session using a tRNS Side Effects Questionnaire (Supplementary Figure S2), adapted from  
244 Brunoni et al. (2011), which collected information regarding the type of adverse event, its  
245 severity, and its causality.

246

#### 247 **Statistical Analyses**

248 All statistical analyses were conducted using SPSS software (IBM SPSS Statistics 25  
249 for Windows; SPSS Inc.). Outcome measures were analysed for change over the sham-  
250 controlled phase using a mixed-effects repeated measures (MERM) model with a restricted  
251 number of covariates. Time was entered as a repeated measures factor with an unstructured  
252 covariance matrix, tRNS Condition (active or sham) was a between-subjects factor, and

253 subjects were included as a random effect. For mood and quality of life outcomes, covariates  
254 were selected based on prior reports of their significant effect on antidepressant response to  
255 transcranial electrical stimulation; these included treatment resistance (Brunoni et al., 2016)  
256 (assessed by the Maudsley Staging Method (Fekadu et al., 2009)), and presence of concurrent  
257 antidepressant medications (Brunoni et al., 2013a; Brunoni et al., 2013c). A MERM model  
258 was similarly used for neuropsychological outcomes, with MADRS mood scores at the  
259 respective time points included as a covariate. Acute cognitive effects following the first  
260 session were examined using a two-way repeated measure analysis of variance  
261 (RMANOVA), with factors of tRNS Condition and Time (pre and post session 1). For the  
262 Emotion Recognition Task, a multivariate ANOVA (MANOVA) was conducted with the  
263 between-subject factor of tRNS Condition.

264 Additional MERM analyses were conducted for the primary outcome measure  
265 (MADRS). Baseline scores on the TEQ were added as a covariate to the MERM analysis to  
266 test whether treatment expectations modified mood outcomes. To assess whether medication  
267 use affected outcomes, each medication class (antidepressants, benzodiazepines,  
268 antipsychotics, lithium and anticonvulsants) was entered as the only covariate in separate  
269 MERM analyses.

270 The number of responders (defined as a reduction in MADRS total score of  $\geq 50\%$   
271 from baseline) and remitters (defined as a final MADRS total score  $< 10$ ) at the end of the  
272 sham-controlled phase were compared between active and sham tRNS groups using a  
273 Fisher's exact test.

274 The association between participant or rater guesses (active or sham) and the  
275 participant's assigned tRNS condition (active or sham) was tested using a Pearson Chi-square  
276 test with Yates' continuity correction. Cohen's kappa statistic was used to assess agreement  
277 between participant and rater guesses.

278 Statistical tests were two-tailed and significance was set at  $p < 0.05$ .

279

## 280 Results

281 A total of 69 participants met inclusion criteria and were randomized to receive either active  
 282 or sham tRNS during the sham-controlled phase (see the CONSORT flow diagram,  
 283 Supplementary Figure S3). A total of 66 participants (sham: 34, active: 32) completed the  
 284 sham-controlled phase and were analysed using a per-protocol approach. Table 1 shows  
 285 demographic and clinical characteristics for active and sham tRNS groups at baseline.

286 **Table 1. Comparison of demographic and clinical characteristics at baseline.**

	Sham	Active
n	34	32
<i>Medications (yes/no)</i>		
Any concurrent medication	27/7	22/10
Antidepressant	23/11	20/12
Lithium	1/33	2/30
Benzodiazepine*	2/32	2/30
Antipsychotic	6/28	4/28
Anticonvulsant	5/29	1/31
<i>Clinical and demographic variables (m, SD)</i>		
Gender (m/f)	19/15	17/15
Melancholic (yes/no)	19/9	12/12
MDD/BP1/BP2	30/3/1	30/0/2
Age (years)	48.8 (12.3)	47.5 (12.0)
Age at onset (years)	27.0 (9.6)	27.5 (9.6)
Duration of current episode (months)	24.4 (32.2)	37.2 (48.0)
Duration of previous episodes (months)	65.9 (65.8)	88.5 (93.6)
Antidepressants failed current episode	2.1 (1.7)	2.6 (2.9)
Total lifetime failed antidepressants	4.0 (3.0)	5.0 (5.1)
Maudsley Staging score	7.3 (2.1)	6.5 (1.9)
Baseline MADRS score	29.5 (4.6)	30.1 (5.0)
Baseline BDI-II score	33.8 (9.1)	34.1 (9.4)
Baseline CGI-S score	4.4 (0.6)	4.4 (0.6)
Baseline Q-LES-SF score	32.8 (10.5)	34.9 (11.2)
Baseline TEQ score	24.5 (7.6)	24.1 (7.1)


287 \*Participants were required to cease benzodiazepine medication use prior to commencing the trial.

288 MDD: Major depressive disorder. BP1/BP2: Bipolar I and bipolar II disorder. MADRS: Montgomery-Asberg Depression  
289 Rating Scale. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. BDI-II: Beck Depression  
290 Inventory. CGI-S: Clinician Global Impression Severity scale, is a 7-point clinician-rated scale ranked from 1-normal to 7-  
291 extremely ill. TEQ: Treatment Expectancy Questionnaire.  
292

## 293 Clinical outcome measures

294 Table 2 shows the results for all MERM analyses of mood and quality of life outcome  
295 measures during the sham-controlled phase. MERM analysis of MADRS scores showed a  
296 significant effect of Time ( $p < 0.001$ ). There was, however, no effect of tRNS Condition ( $p =$   
297  $0.630$ ), and no significant Time  $\times$  Condition interaction ( $p = 0.445$ ; see Figure 1). Results  
298 from intention-to-treat analyses are also reported for all planned outcomes in Supplementary  
299 Table S2, in accordance with CONSORT guidelines for parallel group randomised control  
300 trials (Schulz et al., 2010). Repeating the analysis while incorporating scores from the  
301 Treatment Expectations Questionnaire as an additional covariate did not modify outcomes.  
302 Concurrent medications did not significantly affect outcomes when entered as covariates in  
303 separate MERM analyses (see Supplementary Table S3). Supplementary Table S4 shows  
304 results from MERM analyses of all outcome measures acquired during the acute daily  
305 treatment phases combined (i.e. both sham-controlled and open-label phases). Supplementary  
306 Figure S4 shows graphs of mood and quality of life measures for all time-points up to the 9-  
307 month follow-up assessment.

308 One participant in the active tRNS group (3.1%), and five participants receiving sham  
309 tRNS (14.7%), were considered treatment responders after completion of the sham-controlled  
310 phase (i.e. following 20 sessions of tRNS). Only two participants met the remission criterion,  
311 both in the sham tRNS condition (5.9%). Fisher's exact tests revealed no statistically  
312 significant differences between active and sham tRNS conditions for response ( $p = 0.198$ )  
313 and remission ( $p = 0.493$ ) rates.  
314



315

316

317

318

319

320

**Figure 1. Mood scores.** Graph showing MADRS scores (estimated marginal means  $\pm$  SD) across rating time points, including the sham-controlled phase (from baseline to 4-weeks), open-label phase (from 4 – 8 weeks), and 1-month follow-up assessment following the final taper session. Dotted lines indicate sham tRNS sessions delivered during the sham-controlled phase.

321 **Table 2. Mood and quality of life outcome measures.** Estimated marginal means and results from MERM analyses during the  
 322 sham-controlled phase. MERM analyses were performed including the following covariates: Maudsley staging method total score as a  
 323 measure of treatment resistance, and antidepressant use.

<i>Mood Assessments (m, SEM)</i>	Baseline		Week 2		Week 4		Condition		Time		Time × Condition	
	Sham	Active	Sham	Active	Sham	Active	F	p	F	p	F	p
MADRS	29.1 (0.8)	28.9 (0.8)	24.4 (1.0)	24.8 (1.1)	22.1 (1.2)	23.7 (1.3)	0.24	0.630	41.73	<0.001	0.82	0.445
BDI-II	32.6 (1.7)	33.2 (1.8)	25.2 (1.9)	27.2 (2.0)	22.1 (1.9)	24.9 (2.0)	0.72	0.399	24.56	<0.001	0.46	0.762
CGI-I	-	-	3.5 (0.1)	3.6 (0.1)	3.1 (0.1)	3.4 (0.1)	2.24	0.140	12.69	<0.001	2.10	0.153
Q-LES-SF	32.4 (1.9)	36.0 (2.1)	-	-	43.5 (2.8)	43.9 (2.9)	0.45	0.503	31.67	<0.001	0.84	0.362

324 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale  
 325 ranked from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. m: Mean. SEM: Standard error of measure.  
 326



## 327 Neuroplasticity outcome measures

328 A total of 44 participants (sham: 25, active: 19) completed the optional PAS study to  
329 assess changes in motor cortical excitability. A MERM analysis found no significant effects  
330 of Time ( $p = 0.209$ ) or Condition ( $p = 0.780$ ), and no significant Time  $\times$  Condition interaction  
331 ( $p = 0.570$ ; see Table 3, and Supplementary Figure S5). Furthermore, change in MADRS  
332 scores did not correlate with changes in MEP amplitudes from baseline to the end of the  
333 sham-controlled phase ( $r = -0.02$ ,  $p = 0.905$ ; Supplementary Figure S6).

334

## 335 Neuropsychological outcomes

336 Neuropsychological outcomes during the sham-controlled phase are shown in Table 3. There  
337 were no significant main effects of Time, and no significant Time  $\times$  Condition interaction  
338 effects for all neuropsychological measures.

339 **Table 3. Neuroplasticity and neuropsychological outcome measures.** Estimated marginal means and results from MERM analyses  
 340 during the sham-controlled phase. The neuroplasticity MERM analysis were performed including the following covariates: Maudsley staging  
 341 parameters total score as a measure of treatment resistance, and antidepressant use. Neuropsychological MERM analyses were performed using  
 342 MADRS scores as a covariate.

	Baseline		Week 4		Condition		Time		Time × Condition	
	Sham	Active	Sham	Active	F	p	F	p	F	p
<i>Neuroplasticity Assessment (m, SEM)</i>										
PAS: MEP amplitude	1.24 (0.10)	1.21 (0.12)	1.31 (0.09)	1.40 (0.10)	0.08	0.780	1.63	0.209	0.33	0.570
<i>Neuropsychological Assessments (m, SEM)</i>										
CVLT-II: Trial 1-5 total recall t-score	45.7 (2.8)	48.7 (2.2)	46.3 (2.3)	49.7 (2.2)	2.12	0.148	0.12	0.734	0.01	0.913
CVLT-II: Long delay free recall z-score	-0.41 (0.21)	0.03 (0.22)	-0.64 (0.22)	-0.38 (0.21)	2.69	0.104	1.85	0.176	0.20	0.653
D-KEFS: Letter fluency scaled score	11.2 (0.7)	11.5 (0.7)	10.9 (0.7)	11.9 (0.7)	0.97	0.327	0.01	0.945	0.32	0.575
D-KEFS: Category fluency scaled score	10.3 (0.8)	10.9 (0.8)	9.8 (0.8)	11.8 (0.8)	2.84	0.094	0.05	0.828	0.80	0.372
D-KEFS: Category switching total scaled score	10.0 (0.6)	11.1 (0.6)	9.6 (0.6)	10.6 (0.6)	3.36	0.069	0.50	0.480	0.02	0.888
Ruff 2 & 7: Total speed t-score	47.4 (1.9)	49.9 (1.9)	51.3 (1.9)	53.6 (1.8)	1.66	0.200	3.45	0.066	0.01	0.946
Ruff 2 & 7: Total accuracy t-score	49.6 (2.3)	46.6 (2.4)	50.4 (2.4)	48.7 (2.3)	1.02	0.316	0.34	0.561	0.08	0.779
SDMT: Total correct z-score	-0.31 (0.18)	0.25 (0.18)	-0.02 (0.19)	0.41 (0.18)	7.78	<b>0.006</b>	1.32	0.254	0.15	0.703
WAIS-IV Digit Span: Total correct scaled score	9.7 (0.5)	11.5 (0.6)	10.5 (0.6)	12.6 (0.5)	13.00	<b>&lt;0.001</b>	2.57	0.112	0.12	0.732
CFQ: Total score	50.0 (2.2)	46.8 (2.3)	49.9 (2.3)	50.0 (2.2)	0.52	0.474	0.40	0.528	0.57	0.451

343 PAS: Paired associative stimulation. MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit Modalities Test.  
 344 D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire. m: Mean. SEM: Standard error of measure.  
 345

## 346 Acute cognitive effects

347 For reaction time, the main effects of Time ( $p = 0.404$ ), Condition ( $p = 0.992$ ), and the Time  
 348  $\times$  Condition interaction effect ( $p = 0.949$ ) were not statistically significant. Further, for the  
 349 Emotion Recognition Task the main effect of tRNS Condition was not statistically significant  
 350 ( $p = 0.347$ ).

## 351 Physical adverse events

352 Adverse events occurring during the sham-controlled and open-label phases of the  
 353 trial are presented in Table 4. Side-effects were transient and mild-to-moderate in severity.  
 354 Pearson Chi-square tests revealed significantly more instances of erythema (skin redness;  $p <$   
 355  $0.001$ ), paraesthesia (tingling, burning, and itching sensations;  $p < 0.001$ ), fatigue ( $p = 0.006$ ),  
 356 and dizziness/light-headedness ( $p = 0.002$ ) following active tRNS as compared to sham tRNS  
 357 sessions.

358  
 359 **Table 4. Physical adverse event frequency.** Adverse events are sorted according to  
 360 overall likelihood of occurrence, with events most likely to occur listed first. Differences in  
 361 frequency of adverse event occurrence during the sham-controlled phase was tested using  
 362 Pearson Chi-square tests with Yates' continuity correction.

	Sham-controlled phase						Open-label phase	
	Sham (646 sessions)		Active (650 sessions)		Pearson Chi-square		Active (1161 sessions)	
	n	%	n	%	$\chi^2$	$p$ -value	n	%
Erythema	129	20.0	454	69.8	323.67	<0.001	781	67.3
Tingling	126	19.5	332	51.1	139.96	<0.001	623	53.7
Burning	15	2.3	251	38.6	214.14	<0.001	370	31.9
Itching	40	6.2	97	14.9	25.21	<0.001	170	14.6
Fatigue	33	5.1	60	9.2	7.66	0.006	75	6.5
Headache	43	6.7	30	4.6	2.17	0.141	31	2.7
Dizziness/light-headedness	10	1.5	31	4.8	9.95	0.002	48	4.1
Nausea	7	1.1	15	2.3	2.22	0.136	36	3.1
Scalp Discomfort	7	1.1	9	1.4	0.06	0.811	10	0.9
Other	14	2.2	26	4.0	3.05	0.081	58	5.0

363

## 364 Blinding integrity

365 Participants were asked to guess their treatment condition at the end of the double-  
366 blinded sham-controlled phase. 75% of participants in the sham condition correctly guessed  
367 they received sham tRNS, and 55% of participants in the active condition correctly guessed  
368 they had received active tRNS. A Pearson Chi-square test of participant guesses was  
369 significant ( $\chi^2 = 4.68$ ;  $p = 0.031$ ), suggesting that participants were not adequately blinded to  
370 their treatment condition. To determine whether participant guesses of treatment condition  
371 may have influenced mood outcomes, we performed a post-hoc simple linear regression  
372 analysis; percent change in MADRS score over the 4-week sham-controlled phase was  
373 selected as the dependent variable, and participant guess (active, sham) as the independent  
374 variable. This analysis was not statistically significant ( $R^2 = 0.023$ ,  $F = 1.43$ ,  $p = 0.237$ ).

375 Blinded study raters were similarly asked to guess participants' treatment condition at  
376 the end of the sham-controlled phase. Raters correctly guessed that participants had received  
377 sham tRNS 56% of the time, and active tRNS 31% of the time. A Pearson Chi-square test  
378 found this difference not to be statistically significant ( $\chi^2 = 0.492$ ;  $p = 0.483$ ). Furthermore,  
379 Cohen's kappa showed no agreement between participant and rater guesses ( $\kappa = 0.134$ ;  $p =$   
380  $0.329$ ).

## 381 Discussion

382 Here we report the results of the first randomized control trial to examine the efficacy  
383 of tRNS for the treatment of depression. Although there was a significant reduction of  
384 depressive symptoms over the duration of the study period, there was no difference in the rate  
385 of improvement between sham and active tRNS conditions. Further, there was no significant  
386 effect of tRNS on neuroplasticity measures in the subset of participants that completed the  
387 PAS paradigm, suggesting that stimulation did not increase global cortical excitability. tRNS  
388 was found to be safe with no adverse acute cognitive, neuropsychological or severe physical  
389 side effects. However, tRNS resulted in a higher incidence rate of skin redness (erythema)  
390 and paraesthesia (tingling, itching, and burning sensations) in the active condition, as well as  
391 fatigue and dizziness/light-headedness, which occurred in fewer than 10% of sessions.  
392 Nevertheless, the stimulation protocol was well-tolerated with only one participant dropping-  
393 out due to adverse effects, which were not conclusively associated with tRNS.

394 The results of this study do not support the use of tRNS with the current stimulation  
395 parameters as a therapeutic intervention for the treatment of depression. Despite encouraging  
396 initial evidence of significant reductions in depression scores in patients with fibromyalgia  
397 (Curatolo et al., 2017), and a case report of improvement in MDD (Chan et al., 2012), mood  
398 and quality of life outcomes in the active tRNS group were no different from the placebo-  
399 controlled response in the sham group at all time-points. The size of reductions in depressive  
400 symptoms observed in both conditions of the present study is broadly similar to the sham  
401 condition of previous trials of tDCS for depression (Blumberger et al., 2012; Loo et al.,  
402 2012a; Palm et al., 2012; Brunoni et al., 2013b; Bennabi et al., 2015). Of these previous  
403 tDCS trials, our study design was most similar to a recent international multisite investigation  
404 conducted by our group, which observed improvements in depression scores of 27.8% and  
405 22.3% in sham and active tDCS conditions, respectively, as compared to 24.1% and 18.0% in

406 sham and active tRNS conditions (Loo et al., 2018). We recruited participants using  
407 analogous inclusion/exclusion criteria, participant demographic and clinical characteristics,  
408 and adopted comparable stimulation parameters, at least in terms of treatment duration (30  
409 minutes), session number and frequency (20 daily weekday sessions), and direct current  
410 intensity (2 mA direct current offset in the present study vs a marginally stronger current  
411 intensity of 2.5 mA in the tDCS study). Interestingly, the present tRNS trial and Loo et al.  
412 (2018) have used the highest total number of sessions and strongest stimulation parameters,  
413 including current intensity, compared to other investigations of the antidepressant effects of  
414 transcranial electrical stimulation (Blumberger et al., 2012; Loo et al., 2012a; Palm et al.,  
415 2012; Brunoni et al., 2013b; Bennabi et al., 2015), with both studies reporting no advantage  
416 of active stimulation over sham.

417         The synaptic plasticity hypothesis of depression purports that MDD is characterized  
418 by a partial reduction in long-term potentiation-like processes (Player et al., 2013; Kuhn et  
419 al., 2016), suggesting that impaired synaptic plasticity, particularly in the prefrontal cortex, is  
420 a key feature of the pathophysiology of depression (Goto et al., 2010; Duman et al., 2016;  
421 Noda et al., 2018). This hypothesis is supported by evidence that the therapeutic efficacy of  
422 antidepressants is, at least partly, due to their capacity to increase neural plasticity (Santarelli  
423 et al., 2003; Castrén and Hen, 2013). Similarly, prior work from our group has demonstrated  
424 that a course of tDCS increases neuroplasticity and mood outcomes in depression. However,  
425 a correlation between these measures could not be confirmed due to the limited sample size  
426 ( $n = 18$ ) (Player et al., 2014b). Despite a larger sample size from which to detect small effects  
427 of the intervention, we did not see an increase in neuroplasticity levels following tRNS.  
428 Previous research has shown that tRNS can induce acute neuroplastic after-effects, measured  
429 by investigating changes to motor cortex excitability using TMS motor evoked potentials  
430 (Terney et al., 2008; Chaieb et al., 2015; Ho et al., 2015a). However, there is no evidence to

431 date to suggest cumulative changes in neuroplasticity following a course of multiple repeated  
432 sessions of tRNS, as assessed in this study. An important caveat to our results is that only a  
433 subset of participants (44/69) completed the PAS study. It is theoretically possible that the  
434 subset of participants who underwent the PAS protocol had different clinical, physiological,  
435 or behavioural characteristics (e.g. greater levels of motivation) and may thus not be  
436 representative of the larger sample.

437         The exact purported mechanisms of action for prolonged cortical excitation following  
438 tRNS are unclear, but may include either 1) temporal summation of neural activity when  
439 random noise stimuli and ongoing endogenous neuronal activity occur in close succession  
440 (Fertonani et al., 2011), and/or 2) enhancement of neuronal signalling via the principle of  
441 stochastic resonance (van der Groen and Wenderoth, 2017). The latter refers to signals that  
442 are too weak to exceed a threshold being amplified by adding a random noise stimulus,  
443 improving the signal-to-noise ratio and the synchronization and coherence of neuronal  
444 networks (Moss et al., 2004; Pavan et al., 2019). Though more research is required to  
445 determine which of these mechanisms dominates, the action of tRNS appears to rely heavily  
446 on detection and propagation of weak ongoing endogenous neuronal signals. The notion of  
447 stochastic resonance has been demonstrated in several tRNS experiments aimed at enhancing  
448 sensitivity to sensory inputs, including visual, auditory, and tactile stimuli (van der Groen and  
449 Wenderoth, 2017). Interestingly, investigations of auditory (Rufener et al., 2017) and visual  
450 (Van der Groen et al., 2018) perceptual thresholds have shown that tRNS has its largest effect  
451 on near-threshold stimuli, whereas stimuli clearly above and below threshold were  
452 unaffected. It may be for this reason that the only positive randomized control trials using  
453 tRNS in clinical populations have stimulated the sensory and motor cortices, specifically in  
454 the treatment of tinnitus via the auditory cortex (Vanneste et al., 2013), or stimulation of the  
455 motor cortex for chronic pain in fibromyalgia (Curatolo et al., 2017). tRNS may restore the

456 dysfunctional activity in these cortical structures by normalizing their capacity to filter weak  
457 signals amidst background neural noise. In complex disorders such as depression, however, it  
458 is unclear what the depressed ‘signal’ might be. Studies seeking to use tRNS for other  
459 complex disorders by stimulating prefrontal cortical regions have also reported negative  
460 findings, i.e. for the treatment of multiple sclerosis (Palm et al., 2016b), and vegetative state  
461 (Mancuso et al., 2017). Similarly to depression, these illnesses do not consist of a well-  
462 defined neural signal whose signalling properties can be augmented by tRNS to revert  
463 pathophysiological dysfunctions of brain activity.

464         Although the present study reports null findings for the use of tRNS in depression, it  
465 provides valuable information regarding the safety and tolerability of multiple repeated  
466 sessions of tRNS. To the best of our knowledge, the previous longest delivery of tRNS was  
467 15 sessions (Chan et al., 2012), whereas participants in the current study experienced up to 40  
468 sessions over eight weeks if allocated to the active tRNS condition. Adverse events of  
469 erythema and paraesthesia were reported more frequently in the active tRNS condition as  
470 compared to sham. These results are comparable to those observed in the tDCS literature, in  
471 which meta-analyses similarly suggest a greater frequency of erythema and paraesthesia  
472 (Moffa et al., 2017; Nikolin et al., 2018). Of interest, fatigue and dizziness/light-headedness  
473 were also noted more frequently during active tRNS sessions. These side effects are not a  
474 common adverse effect of tDCS and might be unique to the tRNS stimulation parameters  
475 used in the current study, for example, due to the current intensity ranging as high as 3 mA (2  
476 mA direct offset with  $\pm 1$  mA amplitude fluctuation). Importantly, fatigue and dizziness/light-  
477 headedness occurred rarely, in only 9.2% of sessions for fatigue, and 4.8% for light-  
478 headedness. Additionally, these adverse events were transient, resolved on their own shortly  
479 after cessation of stimulation, and were not reported to be severe in intensity.



480 A limitation of the present study is that blinding was not preserved, possibly due to  
481 the increased incidence of adverse events during active tRNS compared to sham. One would  
482 expect inadequate blinding to reduce placebo effects for participants in the sham condition,  
483 and potentially enhance them for participants receiving active tRNS, thereby increasing the  
484 likelihood of observing a difference between groups. This was not the case in the present  
485 study. Indeed, scores for mood outcomes were quantitatively (but not significantly) better in  
486 the sham condition compared to active tRNS, suggesting that inadequate blinding did not bias  
487 results in favour of the active treatment. Future studies may consider alternative methods to  
488 adequately blind participants, including the use of a topical salve beneath the site of  
489 stimulation to reduce paraesthetic effects and erythema (McFadden et al., 2011; Guarienti et  
490 al., 2015), or comparisons against an active control condition (Fonteneau et al., 2019).

491 A major strength of the present study is the research design, which included double  
492 blinding of participants and raters, examination of mood outcomes in addition to  
493 neuroplasticity changes, comprehensive assessment of adverse events using  
494 neuropsychological and physical measures, reporting of long-term follow-up outcomes up to  
495 9-months following completion of the open-label phase, and rigorous statistical analysis  
496 methodology informed by CONSORT guidelines.

497

## 498 **Conclusion**

499 This study represents the first randomised control trial for the use of tRNS to treat  
500 depression. Our findings do not lend support for the use of tRNS as a therapeutic intervention  
501 for depression. Antidepressant response was similar between active and sham tRNS  
502 conditions. tRNS did not increase motor cortical excitability, a measure of neuroplasticity  
503 associated with antidepressant response in other successful therapeutic clinical trials of

504 depression (Santarelli et al., 2003; Castrén and Hen, 2013). The profile of adverse events for  
505 tRNS was similar to that of tDCS, with a significantly greater likelihood of erythema and  
506 paraesthesia in the active tRNS condition, in addition to a higher incidence rate of fatigue and  
507 dizziness/light-headedness. Participant blinding was not preserved and may be related to the  
508 increased frequency of side effects in the active condition. Overall, the treatment was well-  
509 tolerated by participants.

510

## 511 **Acknowledgements**

512 This study was funded by a National Health and Medical Research Council  
513 (NHMRC) Project Grant: APP1051423.

514

## 515 **Statement of Interest**

516 CL has served on a Janssen Advisory Board for Janssen and received an honorarium  
517 from Mecta for teaching at an international electroconvulsive therapy (ECT) course. The  
518 remaining authors have no conflicts of interest to declare.

519

## 520 References

- 521 Abe T, Miyaguchi S, Otsuru N, Onishi H (2019) The effect of transcranial random noise stimulation on  
522 corticospinal excitability and motor performance. *Neuroscience letters* 705:138-142.
- 523 Ambrus GG, Paulus W, Antal A (2010) Cutaneous perception thresholds of electrical stimulation  
524 methods: comparison of tDCS and tRNS. *Clinical neurophysiology : official journal of the*  
525 *International Federation of Clinical Neurophysiology* 121:1908-1914.
- 526 Beck AT, Steer RA, Brown GK (1996) *Manual for Beck Depression Inventory-II*. San Antonio, TX: The  
527 Psychological Corporation.
- 528 Bennabi D, Nicolier M, Monnin J, Tio G, Pazart L, Vandell P, Haffen E (2015) Pilot study of feasibility of  
529 the effect of treatment with tDCS in patients suffering from treatment-resistant depression  
530 treated with escitalopram. *Clinical neurophysiology* 126:1185-1189.
- 531 Bikson M et al. (2016) Safety of Transcranial Direct Current Stimulation: Evidence Based Update  
532 2016. *Brain Stimulation* 9:641-661.
- 533 Blumberger D, Tran L, Fitzgerald P, Hoy KB, Daskalakis ZJ (2012) A randomized double-blind sham-  
534 controlled study of transcranial direct current stimulation for treatment-resistant major  
535 depression. *Frontiers in psychiatry* 3:74.
- 536 Broadbent DE, Cooper PF, FitzGerald P, Parkes KR (1982) The Cognitive Failures Questionnaire (CFQ)  
537 and its correlates. *Br J Clin Psychol* 21:1-16.
- 538 Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F (2011) A systematic review on  
539 reporting and assessment of adverse effects associated with transcranial direct current  
540 stimulation. *International Journal of Neuropsychopharmacology* 14:1133-1145.
- 541 Brunoni AR, Ferrucci R, Bortolomasi M, Scelzo E, Boggio PS, Fregni F, Dell'Osso B, Giacomuzzi M,  
542 Altamura AC, Priori A (2013a) Interactions between transcranial direct current stimulation  
543 (tDCS) and pharmacological interventions in the Major Depressive Episode: findings from a  
544 naturalistic study. *Eur Psychiatry* 28:356-361.
- 545 Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA,  
546 Bensenor IM, Fregni F (2013b) The sertraline vs electrical current therapy for treating  
547 depression clinical study: results from a factorial, randomized, controlled trial. *JAMA*  
548 *psychiatry* 70:383-391.
- 549 Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA,  
550 Bensenor IM, Fregni F (2013c) The sertraline vs. electrical current therapy for treating  
551 depression clinical study: results from a factorial, randomized, controlled trial. *JAMA*  
552 *Psychiatry* 70:383-391.
- 553 Brunoni AR, Moffa AH, Sampaio-Junior B, Borriore L, Moreno ML, Fernandes RA, Veronezi BP,  
554 Nogueira BS, Aparicio LV, Razza LB (2017) Trial of electrical direct-current therapy versus  
555 escitalopram for depression. *New England Journal of Medicine* 376:2523-2533.
- 556 Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D,  
557 Haffen E, Alonzo A, Loo CK (2016) Transcranial direct current stimulation for acute major  
558 depressive episodes: meta-analysis of individual patient data. *Br J Psychiatry* 208:522-531.
- 559 Castrén E, Hen R (2013) Neuronal plasticity and antidepressant actions. *Trends in neurosciences*  
560 36:259-267.
- 561 Chaieb L, Antal A, Paulus W (2015) Transcranial random noise stimulation-induced plasticity is  
562 NMDA-receptor independent but sodium-channel blocker and benzodiazepines sensitive.  
563 *Frontiers in neuroscience* 9:125-125.
- 564 Chan HN, Alonzo A, Martin DM, Player M, Mitchell PB, Sachdev P, Loo CK (2012) Treatment of major  
565 depressive disorder by transcranial random noise stimulation: case report of a novel  
566 treatment. *Biological psychiatry* 72:e9-e10.
- 567 Contemori G, Trotter Y, Cottureau BR, Maniglia M (2019) tRNS boosts perceptual learning in  
568 peripheral vision. *Neuropsychologia* 125:129-136.

- 569 Curatolo M, La GB, Cosentino G, Baschi R, Salemi G, Talotta R, Romano M, Triolo G, De MT, Fierro B  
570 (2017) Motor cortex tRNS improves pain, affective and cognitive impairment in patients with  
571 fibromyalgia: preliminary results of a randomised sham-controlled trial. *Clinical and*  
572 *experimental rheumatology* 35:100-105.
- 573 Delis DC, Kaplan E, Kramer JH (2001) *Delis-Kaplan Executive Function System (D-KEFS)*. San Antonio,  
574 TX: The Psychological Corporation.
- 575 Delis DC, Kramer JH, Kaplan E, Ober BA (2000) *California Verbal Learning Test (2nd ed.)*. San Antonio,  
576 TX: The Psychological Corporation.
- 577 Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016) Synaptic plasticity and depression: new  
578 insights from stress and rapid-acting antidepressants. *Nature medicine* 22:238.
- 579 Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of Life Enjoyment and Satisfaction  
580 Questionnaire: a new measure. *Psychopharmacol Bull* 29:321-326.
- 581 Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ (2009) A  
582 multidimensional tool to quantify treatment resistance in depression: the Maudsley staging  
583 method. *The Journal of clinical psychiatry* 70:177-184.
- 584 Fertonani A, Pirulli C, Miniussi C (2011) Random noise stimulation improves neuroplasticity in  
585 perceptual learning. *The Journal of neuroscience : the official journal of the Society for*  
586 *Neuroscience* 31:15416-15423.
- 587 Fonteneau C, Mondino M, Arns M, Baeken C, Bikson M, Brunoni AR, Burke MJ, Neuvonen T, Padberg  
588 F, Pascual-Leone A (2019) Sham tDCS: A hidden source of variability? Reflections for further  
589 blinded, controlled trials. *Brain stimulation*.
- 590 Ghin F, Pavan A, Contillo A, Mather G (2018) The effects of high-frequency transcranial random noise  
591 stimulation (hf-tRNS) on global motion processing: An equivalent noise approach. *Brain*  
592 *Stimul* 11:1263-1275.
- 593 Goto Y, Yang CR, Otani S (2010) Functional and dysfunctional synaptic plasticity in prefrontal cortex:  
594 roles in psychiatric disorders. *Biological psychiatry* 67:199-207.
- 595 Guarienti F, Caumo W, Shiozawa P, Cordeiro Q, Boggio PS, Benseñor IM, Lotufo PA, Bikson M,  
596 Brunoni AR (2015) Reducing transcranial direct current stimulation-induced erythema with  
597 skin pretreatment: considerations for sham-controlled clinical trials. *Neuromodulation:*  
598 *Technology at the Neural Interface* 18:261-265.
- 599 Guy W (1976) *ECDEU Assessment Manual for Psychopharmacology*. Rockville, MD.: U.S. Department  
600 of Health, Education, and Welfare.
- 601 Haesebaert F, Mondino M, Saoud M, Poulet E, Brunelin J (2014) Efficacy and safety of fronto-  
602 temporal transcranial random noise stimulation (tRNS) in drug-free patients with  
603 schizophrenia: a case study. *Schizophrenia research* 159:251-252.
- 604 Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ (2015) Response of depression to  
605 electroconvulsive therapy: a meta-analysis of clinical predictors. *The Journal of clinical*  
606 *psychiatry* 76:1374-1384.
- 607 Hayward KS, Brauer SG, Ruddy KL, Lloyd D, Carson RG (2017) Repetitive reaching training combined  
608 with transcranial Random Noise Stimulation in stroke survivors with chronic and severe arm  
609 paresis is feasible: a pilot, triple-blind, randomised case series. *Journal of neuroengineering*  
610 *and rehabilitation* 14:46.
- 611 Ho K-A, Taylor JL, Loo CK (2015a) Comparison of the effects of transcranial random noise stimulation  
612 and transcranial direct current stimulation on motor cortical excitability. *The journal of ECT*  
613 31:67-72.
- 614 Ho KA, Taylor JL, Loo CK (2015b) Comparison of the effects of transcranial random noise stimulation  
615 and transcranial direct current stimulation on motor cortical excitability. *The journal of ECT*  
616 31:67-72.
- 617 Inukai Y, Saito K, Sasaki R, Tsuiki S, Miyaguchi S, Kojima S, Masaki M, Otsuru N, Onishi H (2016)  
618 Comparison of Three Non-Invasive Transcranial Electrical Stimulation Methods for Increasing  
619 Cortical Excitability. *Front Hum Neurosci* 10:668-668.

- 620 Jooss A, Haberbosch L, Kohn A, Ronnefarth M, Bathe-Peters R, Kozarzewski L, Fleischmann R, Scholz  
621 M, Schmidt S, Brandt SA (2019) Motor Task-Dependent Dissociated Effects of Transcranial  
622 Random Noise Stimulation in a Finger-Tapping Task Versus a Go/No-Go Task on Corticospinal  
623 Excitability and Task Performance. *Frontiers in neuroscience* 13:161.
- 624 Kreuzer PM, Vielsmeier V, Poeppel TB, Langguth B (2017) A Case Report on Red Ear Syndrome with  
625 Tinnitus Successfully Treated with Transcranial Random Noise Stimulation. *Pain physician*  
626 20:E199-e205.
- 627 Kuhn M, Mainberger F, Feige B, Maier JG, Mall V, Jung NH, Reis J, Klöppel S, Normann C, Nissen C  
628 (2016) State-dependent partial occlusion of cortical LTP-like plasticity in major depression.  
629 *Neuropsychopharmacology* 41:1521.
- 630 Liu W, Ge T, Leng Y, Pan Z, Fan J, Yang W, Cui R (2017) The Role of Neural Plasticity in Depression:  
631 From Hippocampus to Prefrontal Cortex. *Neural Plast* 2017:6871089.
- 632 Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P (2012a) Transcranial direct current  
633 stimulation for depression: 3-week, randomised, sham-controlled trial. *The British Journal of*  
634 *Psychiatry* 200:52-59.
- 635 Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P (2012b) Transcranial direct current  
636 stimulation for depression: 3-week, randomised, sham-controlled trial. *Br J Psychiatry*  
637 200:52-59.
- 638 Loo CK, Sachdev P, Martin D, Pigot M, Alonzo A, Malhi GS, Lagopoulos J, Mitchell P (2010) A double-  
639 blind, sham-controlled trial of transcranial direct current stimulation for the treatment of  
640 depression. *Int J Neuropsychopharmacol* 13:61-69.
- 641 Loo CK, Husain MM, McDonald WM, Aaronson S, O'Reardon JP, Alonzo A, Weickert CS, Martin DM,  
642 McClintock SM, Mohan A (2018) International randomized-controlled trial of transcranial  
643 Direct Current Stimulation in depression. *Brain Stimulation: Basic, Translational, and Clinical*  
644 *Research in Neuromodulation* 11:125-133.
- 645 Mammarella N, Di Domenico A, Palumbo R, Fairfield B (2017) Self-generation and positivity effects  
646 following transcranial random noise stimulation in medial prefrontal cortex: A reality  
647 monitoring task in older adults. *Cortex; a journal devoted to the study of the nervous system*  
648 *and behavior* 91:186-196.
- 649 Mancuso M, Abbruzzese L, Canova S, Landi G, Rossi S, Santarnecchi E (2017) Transcranial random  
650 noise stimulation does not improve behavioral and neurophysiological measures in patients  
651 with subacute vegetative-unresponsive wakefulness state (VS-UWS). *Frontiers in human*  
652 *neuroscience* 11:524.
- 653 McFadden JL, Borckardt JJ, George MS, Beam W (2011) Reducing procedural pain and discomfort  
654 associated with transcranial direct current stimulation. *Brain stimulation* 4:38-42.
- 655 Moffa AH, Brunoni AR, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D,  
656 Haffen E, Alonzo A (2017) Safety and acceptability of transcranial direct current stimulation  
657 for the acute treatment of major depressive episodes: Analysis of individual patient data.  
658 *Journal of affective disorders* 221:1-5.
- 659 Moliadze V, Fritzsche G, Antal A (2014) Comparing the efficacy of excitatory transcranial stimulation  
660 methods measuring motor evoked potentials. *Neural Plast* 2014:837141-837141.
- 661 Montagne B, Kessels RP, De Haan EH, Perrett DI (2007) The Emotion Recognition Task: a paradigm to  
662 measure the perception of facial emotional expressions at different intensities. *Perceptual*  
663 *and motor skills* 104:589-598.
- 664 Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. *Br J*  
665 *Psychiatry* 134:382-389.
- 666 Moss F, Ward LM, Sannita WG (2004) Stochastic resonance and sensory information processing: a  
667 tutorial and review of application. *Clinical neurophysiology : official journal of the*  
668 *International Federation of Clinical Neurophysiology* 115:267-281.
- 669 Mutz J, Edgcumbe DR, Brunoni AR, Fu CHY (2018) Efficacy and acceptability of non-invasive brain  
670 stimulation for the treatment of adult unipolar and bipolar depression: A systematic review

- 671 and meta-analysis of randomised sham-controlled trials. *Neuroscience and biobehavioral*  
672 *reviews* 92:291-303.
- 673 Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK (2017) Safety of repeated sessions of transcranial  
674 direct current stimulation: A systematic review. *Brain Stimulation*.
- 675 Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK (2018) Safety of repeated sessions of transcranial  
676 direct current stimulation: A systematic review. *Brain Stimulation: Basic, Translational, and*  
677 *Clinical Research in Neuromodulation* 11:278-288.
- 678 Nitsche M, Paulus W (2001) Sustained excitability elevations induced by transcranial DC motor  
679 cortex stimulation in humans. *Neurology* 57:1899-1901.
- 680 Nitsche MA, Cohen LG, Wassermann EM, Priori A, Lang N, Antal A, Paulus W, Hummel F, Boggio PS,  
681 Fregni F, Pascual-Leone A (2008) Transcranial direct current stimulation: State of the art  
682 2008. *Brain Stimul* 1:206-223.
- 683 Noda Y, Zomorodi R, Vila-Rodriguez F, Downar J, Farzan F, Cash RF, Rajji TK, Daskalakis ZJ,  
684 Blumberger DM (2018) Impaired neuroplasticity in the prefrontal cortex in depression  
685 indexed through paired associative stimulation. *Depression and anxiety* 35:448-456.
- 686 Palm U, Schiller C, Fintescu Z, Obermeier M, Keeser D, Reisinger E, Pogarell O, Nitsche M, Möller H-J,  
687 Padberg F (2012) Transcranial direct current stimulation in treatment resistant depression: a  
688 randomized double-blind, placebo-controlled study. *Brain stimulation* 5:242-251.
- 689 Palm U, Chalah MA, Padberg F, Al-Ani T, Abdellaoui M, Sorel M, Dimitri D, Créange A, Lefaucheur JP,  
690 Ayache SS (2016a) Effects of transcranial random noise stimulation (tRNS) on affect, pain  
691 and attention in multiple sclerosis. *Restorative neurology and neuroscience* 34:189-199.
- 692 Palm U, Chalah MA, Padberg F, Al-Ani T, Abdellaoui M, Sorel M, Dimitri D, Créange A, Lefaucheur J-P,  
693 Ayache SS (2016b) Effects of transcranial random noise stimulation (tRNS) on affect, pain  
694 and attention in multiple sclerosis. *Restorative neurology and neuroscience* 34:189-199.
- 695 Pavan A, Ghin F, Contillo A, Milesi C, Campana G, Mather G (2019) Modulatory mechanisms  
696 underlying high-frequency transcranial random noise stimulation (hf-tRNS): A combined  
697 stochastic resonance and equivalent noise approach. *Brain Stimul*.
- 698 Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms.  
699 *Neuropsychopharmacology : official publication of the American College of*  
700 *Neuropsychopharmacology* 33:88-109.
- 701 Player MJ, Taylor JL, Alonzo A, Loo CK (2012) Paired associative stimulation increases motor cortex  
702 excitability more effectively than theta-burst stimulation. *Clinical neurophysiology : official*  
703 *journal of the International Federation of Clinical Neurophysiology* 123:2220-2226.
- 704 Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev P, Martin D, Mitchell PB, Loo CK (2013)  
705 Neuroplasticity in depressed individuals compared with healthy controls.  
706 *Neuropsychopharmacology* 38:2101.
- 707 Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev PS, Martin D, Mitchell PB, Loo CK (2014a)  
708 Increase in PAS-induced neuroplasticity after a treatment course of transcranial direct  
709 current stimulation for depression. *J Affect Disord* 167:140-147.
- 710 Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev PS, Martin D, Mitchell PB, Loo CK (2014b)  
711 Increase in PAS-induced neuroplasticity after a treatment course of transcranial direct  
712 current stimulation for depression. *Journal of affective disorders* 167:140-147.
- 713 Popescu T, Krause B, Terhune DB, Twose O, Page T, Humphreys G, Cohen Kadosh R (2016)  
714 Transcranial random noise stimulation mitigates increased difficulty in an arithmetic learning  
715 task. *Neuropsychologia* 81:255-264.
- 716 Rufener KS, Ruhnau P, Heinze H-J, Zaehle T (2017) Transcranial random noise stimulation (tRNS)  
717 shapes the processing of rapidly changing auditory information. *Frontiers in cellular*  
718 *neuroscience* 11:162.
- 719 Rufener KS, Geyer U, Janitzky K, Heinze HJ, Zaehle T (2018) Modulating auditory selective attention  
720 by non-invasive brain stimulation: Differential effects of transcutaneous vagal nerve

- 721 stimulation and transcranial random noise stimulation. *The European journal of*  
722 *neuroscience* 48:2301-2309.
- 723 Ruff RM, Allen CC (1996) *Ruff 2 and 7 Selective Attention Test Professional Manual*. Odessa, FL:  
724 Psychological Assessment Resources, Inc.
- 725 Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME,  
726 Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M  
727 (2006) Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several  
728 Treatment Steps: A STAR\*D Report. *Am J Psychiatry* 163:1905-1917.
- 729 Salemi G, Vazzoler G, Ragonese P, Bianchi A, Cosentino G, Croce G, Gangitano M, Portera E,  
730 Realmuto S, Fierro B, Brighina F (2019) Application of tRNS to improve multiple sclerosis  
731 fatigue: a pilot, single-blind, sham-controlled study. *Journal of neural transmission* (Vienna,  
732 Austria : 1996).
- 733 Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O  
734 (2003) Requirement of hippocampal neurogenesis for the behavioral effects of  
735 antidepressants. *science* 301:805-809.
- 736 Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting  
737 parallel group randomised trials. *BMC medicine* 8:18.
- 738 Shalev N, De Wandel L, Dockree P, Demeyere N, Chechacz M (2018) Beyond time and space: The  
739 effect of a lateralized sustained attention task and brain stimulation on spatial and selective  
740 attention. *Cortex; a journal devoted to the study of the nervous system and behavior*  
741 107:131-147.
- 742 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC  
743 (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and  
744 validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *The*  
745 *Journal of clinical psychiatry* 59 Suppl 20:22-33;quiz 34-57.
- 746 Smith A (1991) *Symbol Digit Modalities Test*. Los Angeles, CA: Western Psychological Services.
- 747 Snowball A, Tachtsidis I, Popescu T, Thompson J, Delazer M, Zamarian L, Zhu T, Kadosh RC (2013)  
748 Long-term enhancement of brain function and cognition using cognitive training and brain  
749 stimulation. *Current Biology* 23:987-992.
- 750 Stefan K, Wycislo M, Classen J (2004) Modulation of associative human motor cortical plasticity by  
751 attention. *Journal of neurophysiology* 92:66-72.
- 752 Szymkowicz SM, McLaren ME, Suryadevara U, Woods AJ (2016) Transcranial Direct Current  
753 Stimulation Use in the Treatment of Neuropsychiatric Disorders: A Brief Review. *Psychiatric*  
754 *annals* 46:642-646.
- 755 Terney D, Chaieb L, Moliadze V, Antal A, Paulus W (2008) Increasing human brain excitability by  
756 transcranial high-frequency random noise stimulation. *Journal of Neuroscience* 28:14147-  
757 14155.
- 758 Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH,  
759 Lebowitz B, McGrath PJ (2006) Evaluation of outcomes with citalopram for depression using  
760 measurement-based care in STAR\* D: implications for clinical practice. *American journal of*  
761 *Psychiatry* 163:28-40.
- 762 Tyler SC, Conto F, Battelli L (2018) Rapid Improvement on a Temporal Attention Task within a Single  
763 Session of High-frequency Transcranial Random Noise Stimulation. *Journal of cognitive*  
764 *neuroscience* 30:656-666.
- 765 van der Groen O, Wenderoth N (2017) Random noise stimulation of the cortex: stochastic resonance  
766 enhances central mechanisms of perception. *Brain Stimulation: Basic, Translational, and*  
767 *Clinical Research in Neuromodulation* 10:e4.
- 768 Van der Groen O, Tang MF, Wenderoth N, Mattingley JB (2018) Stochastic resonance enhances the  
769 rate of evidence accumulation during combined brain stimulation and perceptual decision-  
770 making. *PLoS computational biology* 14:e1006301.

- 771 Vanneste S, Fregni F, De Ridder D (2013) Head-to-head comparison of transcranial random noise  
772 stimulation, transcranial AC stimulation, and transcranial DC stimulation for tinnitus.  
773 Frontiers in psychiatry 4:158.  
774 Wechsler D (2008) Wechsler Adult Intelligence Scale (4th ed.). San Antonio, TX: Pearson.  
775



## 776 **Supplementary Materials**

### 777 Paired associative stimulation methods

778 Participants sat in a comfortable, relaxed position with both hands on a pillow. The  
779 optimal site for eliciting motor evoked potentials (MEPs) in the right first dorsal interosseous  
780 (FDI) muscle was first established and marked on the scalp. Each participant's resting motor  
781 threshold (RMT) – defined as the minimum stimulus intensity to evoke MEPs of  $\geq 50$   $\mu$ V in  
782 the relaxed FDI in 5 out of 10 consecutive trials of single-pulse TMS – was then measured.  
783 TMS intensity for evoking test MEPs was adjusted individually for each participant to elicit  
784 an average 1 mV response. TMS intensity for testing MEPs was limited to a maximum of  
785 130% of RMT even if the actual intensity needed to elicit a 1 mV response was greater.

786 For the stimulation protocol, single-pulse TMS (130% of RMT) to the FDI  
787 representation on the left motor cortex was combined with electrical stimuli (200  $\mu$ s duration,  
788 300% perceptual threshold, DS7 stimulator; Digitimer Co. Ltd., Hertfordshire, UK) to the  
789 right ulnar nerve proximal to the wrist. Two hundred pairs of stimuli (TMS and ulnar nerve)  
790 were given at 0.25 Hz over ~13 minutes. In each pair, ulnar nerve stimulation preceded TMS  
791 by 25 ms. Electrical stimuli were delivered occasionally to the right index finger during PAS.  
792 Participants counted the stimuli and reported the number at the end of the session to ensure  
793 sensory attention to the hand (Stefan et al., 2004). The MEPs recorded before and after PAS  
794 to assess cortical excitability consisted of testing blocks of 20 MEPs at a rate of 0.1 Hz. Two  
795 blocks of MEPs were recorded at baseline. A block of MEPs was recorded immediately after  
796 PAS and then every 10 mins for one hour. During all stimulation, EMG from the FDI was  
797 monitored to ensure muscle relaxation. MEPs were discarded if EMG showed substantial  
798 muscle activity (i.e. peak-to-peak amplitude  $\geq 50$   $\mu$ V) in the time window prior to the TMS  
799 stimuli. Additionally, block-averaged MEP amplitudes were considered outliers if they were

800 more than 4 standard deviations from the mean for active and sham tRNS conditions  
801 combined.  
802 EMG activity was recorded through Ag/AgCl surface electrodes over the right FDI. EMG  
803 was amplified, bandpass filtered (16–1000 Hz), and digitized (2000 Hz) (Cambridge  
804 Electronics Design, Cambridge, UK). TMS (Magstim 200 stimulator, Magstim Co.,  
805 Whitland, UK) was applied using a 70-mm figure-of eight coil oriented with the handle  
806 posterolateral, 45° to the parasagittal plane.

807 **Supplementary Table S1. Schedule of assessments.**

	Baseline	Sham-controlled phase				Open-label phase				Taper phase			
	Week	Wk 0	Wk 1	Wk 2	Wk 3	Wk 4	Wk 1	Wk 2	Wk 3	Wk 4	Wk 1	Wk 2	Wk 3
Session	Pre 1	1-5	6-10	11-15	16-20	21-25	26-30	31-35	36-40	41	42	43	44
<i>Mood Assessments</i>													
MADRS	X		X		X		X		X				X
BDI-II	X	X	X	X	X	X	X	X	X	X	X	X	X
CGI-S	X												
CGI-I			X		X		X		X				X
Q-LES-SF	X				X				X				X
<i>Neurophysiological Assessments</i>													
PAS	X				X				X				
<i>Neuropsychological Assessments</i>													
CVLT-II	X				X				X				
Ruff 2 & 7	X				X				X				
WAIS-IV Digit Span	X				X				X				
SDMT	X				X				X				
D-KEFS Verbal Fluency	X				X				X				
CFQ	X				X				X				

808 Wk: Week. MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-S: Clinician Global Impression Severity scale, is a 7-point clinician-rated scale  
809 ranked from 1-normal to 7-extremely ill. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse. Q-  
810 LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. PAS: Paired associative stimulation. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult  
811 Intelligence Scale. SDMT: Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire

812 **Supplementary Table S2. Intention-to-treat analyses.**

813 Estimated marginal means and results from MERM analyses during the sham-controlled phase, including the following covariates: Maudsley  
 814 staging parameters total score as a measure of treatment resistance, and antidepressant use. Mood, quality of life, neuroplasticity, and  
 815 neuropsychological outcome measures are reported using an intention-to-treat analysis approach.

	Baseline		Week 2		Week 4		Condition		Time		Time × Condition	
	Sham	Active	Sham	Active	Sham	Active	F	p	F	p	F	p
<i>Mood Assessments (m, SEM)</i>												
MADRS	29.1 (0.8)	29.0 (0.8)	24.4 (1.0)	24.8 (1.1)	22.1 (1.2)	23.7 (1.3)	0.29	0.593	43.09	<0.001	0.77	0.467
BDI-II	32.4 (1.6)	33.4 (1.7)	24.9 (1.9)	27.1 (2.0)	21.9 (1.9)	25.1 (2.0)	1.07	0.306	25.07	<0.001	0.58	0.678
CGI-I	-	-	3.5 (0.1)	3.6 (0.1)	3.1 (0.1)	3.4 (0.1)	2.60	0.112	13.07	<0.001	1.98	0.165
Q-LES-SF	32.5 (1.8)	35.8 (2.0)	-	-	43.6 (2.8)	43.8 (2.9)	0.37	0.545	32.00	<0.001	0.80	0.376
<i>Neuroplasticity Assessments (m, SEM)</i>												
PAS: MEP amplitude	1.24 (0.10)	1.21 (0.12)	-	-	1.31 (0.09)	1.40 (0.10)	0.08	0.780	1.63	0.209	0.33	0.570
<i>Neuropsychological Assessments (m, SEM)</i>												
CVLT-II: Trial 1-5 total recall t-score	45.7 (2.2)	48.8 (2.2)	-	-	46.3 (2.3)	49.7 (2.1)	2.29	0.133	0.10	0.751	0.01	0.943
CVLT-II: Long delay free recall z-score	-0.42 (0.21)	0.03 (0.21)	-	-	-0.64 (0.22)	-0.39 (0.21)	2.82	0.096	1.93	0.167	0.23	0.635
D-KEFS: Letter fluency scaled score	11.2 (0.7)	11.6 (0.7)	-	-	10.9 (0.7)	11.9 (0.7)	1.18	0.280	0.00	0.991	0.21	0.648
D-KEFS: Category fluency scaled score	10.3 (0.8)	10.9 (0.8)	-	-	9.9 (0.8)	11.7 (0.8)	1.64	0.204	0.07	0.789	1.78	0.187
D-KEFS: Category switching total scaled score	10.0 (0.6)	11.2 (0.6)	-	-	9.6 (0.6)	10.6 (0.6)	3.61	0.060	0.56	0.454	0.04	0.850
Ruff 2 & 7: Total speed t-score	47.4 (1.9)	50.6 (1.9)	-	-	51.4 (1.9)	53.6 (1.9)	2.17	0.144	2.97	0.087	0.07	0.789
Ruff 2 & 7: Total accuracy t-score	49.6 (2.3)	46.5 (2.3)	-	-	50.4 (2.4)	48.7 (2.3)	1.07	0.302	0.36	0.547	0.09	0.764
SDMT: Total correct z-score	-0.31 (0.17)	0.22 (0.18)	-	-	0.00 (0.18)	0.40 (0.17)	4.10	<b>0.047</b>	4.38	<b>0.039</b>	0.53	0.469
WAIS-IV Digit Span: Total correct scaled score	9.7 (0.5)	11.5 (0.5)	-	-	10.5 (0.6)	12.6 (0.5)	13.67	<0.001	2.50	0.116	0.09	0.771

CFQ: Total score	50.1 (2.2)	46.6 (2.2)	-	-	49.9 (2.3)	50.0 (2.2)	0.61	0.435	0.45	0.501	0.70	0.406
------------------	------------	------------	---	---	------------	------------	------	-------	------	-------	------	-------

816 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale ranked  
817 from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. PAS: Paired associative stimulation. MEP: motor  
818 evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System.  
819 CFQ: Cognitive Failures Questionnaire. m: Mean. SEM: Standard error of measures

820 **Supplementary Table S3. MADRS mixed-effects repeated measures analyses**  
821 **using other covariates.**  
822 Results from MERM analyses during the sham-controlled phase to examine the impact of  
823 medications and treatment expectations as covariates on mood outcomes (i.e. MADRS  
824 scores).

	Covariate		Time		Condition		Time x Condition	
	F	p	F	p	F	p	F	p
Baseline TEQ	0.28	0.599	40.93	<b>&lt;0.001</b>	0.99	0.325	1.32	0.276
Antidepressants	1.14	0.289	44.28	<b>&lt;0.001</b>	2.03	0.160	1.11	0.335
Lithium	3.73	0.058	44.20	<b>&lt;0.001</b>	2.24	0.140	1.14	0.327
Benzodiazepine*	2.48	0.120	44.24	<b>&lt;0.001</b>	1.88	0.175	1.12	0.332
Antipsychotics	1.78	0.188	44.22	<b>&lt;0.001</b>	2.15	0.147	1.12	0.332
Anticonvulsants	0.34	0.561	44.26	<b>&lt;0.001</b>	2.10	0.152	1.12	0.332

825 \*Participants were required to cease benzodiazepine medication use prior to commencing the trial.  
826 TEQ: Treatment Expectations Questionnaire

827 **Supplementary Table S4. Mood, quality of life, neuroplasticity and**  
 828 **neuropsychological outcome measures.**  
 829 Results from MERM analyses during the acute daily treatment phases combined (i.e. tRNS  
 830 received during the sham-controlled and open-label phases).

	Condition		Time		Time × Condition	
	F	p	F	p	F	p
<i>Mood Assessments (m, SEM)</i>						
MADRS	1.09	0.300	29.39	<b>&lt;0.001</b>	0.75	0.560
BDI-II	2.38	0.128	17.60	<b>&lt;0.001</b>	1.00	0.447
CGI-I	6.02	<b>0.017</b>	15.84	<b>&lt;0.001</b>	1.72	0.173
Q-LES-SF	0.00	0.967	30.00	<b>&lt;0.001</b>	1.39	0.257
<i>Neuroplasticity Assessments (m, SEM)</i>						
PAS: MEP amplitude	0.40	0.530	2.11	0.135	0.72	0.193
<i>Neuropsychological Assessments (m, SEM)</i>						
CVLT-II: Trial 1-5 total recall t-score	4.47	<b>0.036</b>	3.12	<b>0.046</b>	0.17	0.844
CVLT-II: Long delay free recall z-score	5.40	<b>0.021</b>	3.03	0.051	0.23	0.799
D-KEFS: Letter fluency scaled score	2.70	0.102	0.14	0.867	0.38	0.683
D-KEFS: Category fluency scaled score	1.97	0.165	0.74	0.477	1.69	0.190
D-KEFS: Category switching total scaled score	2.94	0.088	1.07	0.346	0.24	0.786
Ruff 2 & 7: Total speed t-score	2.94	0.088	3.50	<b>0.032</b>	0.06	0.946
Ruff 2 & 7: Total accuracy t-score	0.80	0.372	0.73	0.482	0.22	0.805
SDMT: Total correct z-score	3.58	0.063	2.80	0.065	1.11	0.335
WAIS-IV Digit Span: Total correct scaled score	17.17	<b>&lt;0.001</b>	2.05	0.132	0.06	0.945
CFQ: Total score	0.20	0.659	0.12	0.891	0.45	0.639

831 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global  
 832 Impression Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse.  
 833 Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. PAS: Paired associative stimulation.  
 834 MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT:  
 835 Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire.  
 836 m: Mean. SEM: Standard error of measures

837 **Supplementary Figure S1. Treatment Expectations Questionnaire**

**Treatment Expectations Questionnaire – Views on DCS**

**Participant ID** \_\_\_\_\_ **Date** \_\_\_\_\_ **Session** \_\_\_\_\_

Please answer the following questions about how effective you think DCS will be in helping improve some symptoms of depression you may be experiencing. If you are not currently experiencing the symptom, please circle NA.

**1) How effective do you think DCS will be for improving your **sleep**?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with sleep

**2) How effective do you think DCS will be for reducing feelings of sadness?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with feeling sad

**3) How effective do you think DCS will be for improving your **appetite**?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with my appetite

**4) How effective do you think DCS will be for improving your **concentration/decision making**?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with concentration/decision making

**5) How effective do you think DCS will be for reducing thoughts of death or suicide?**



1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with thoughts of death or suicide

6) How effective do you think DCS will be for improving your **general interest in things and/or your ability to enjoy things?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with general interest/ enjoying things

7) How effective do you think DCS will be for improving your **energy level?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with my energy levels

8) **OVERALL**, how effective do you think DCS will be for helping to improve the symptoms you are currently experiencing?

1	2	3	4	5
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective

9) Are there any particular reasons why you believe DCS will or will not be effective?

---



---



---



---



---



---

---

---

---

---

**END OF QUESTIONNAIRE**

841 **Supplementary Figure S2. tRNS Side Effects Questionnaire**

Side Effect	Before	During	After	Severity*	Causality <sup>#</sup>
<b>Redness</b> anode cathode					
<b>Tingling/Itching/Burning/Pain</b> anode cathode					
<b>Nausea</b>					
<b>Lightheadedness/Dizziness</b>					
<b>Headache</b>					
<b>Blurred Vision</b>					
<b>Fatigue</b>					
<b>Other:</b>					


\*Severity: 1 = Mild; 2 = Moderate; 3 = Severe. If participant had a side effect after the previous tRNS session, ask when it started and for how long and record in the 'Before' column.

<sup>#</sup>Causality: 1 = Probably Related; 2 = Possibly Related; 3 = Probably Not Related; 4 = Not Related

843 **Supplementary Figure S3. CONSORT flow diagram.**

844 The study was registered at:


845 <https://clinicaltrials.gov/ct2/show/NCT01792414> (ID: NCT01792414).




846

847 **Supplementary Figure S4. Follow-up mood outcome measures.**


848 Graphs showing mood and quality of life scores (unadjusted means  $\pm$  SD) from baseline up to  
849 the 9-month follow-up assessment following completion of the open-label phase. Sample  
850 sizes used for the calculation of summary statistics are presented for each time-point. **A)**  
851 Montgomery-Asberg Depression Rating Scale (MADRS) scores. **B)** Beck Depression  
852 Inventory (BDI-II) scores. **C)** Clinician Global Impression Severity (CGI-S) at baseline, and  
853 CGI-Improvement (CGI-I) scores; the CGI-S is a 7-point clinician-rated scale ranked from 1-  
854 normal (not at all ill) to 7-among most extremely ill patients. The CGI-I is a 7-point clinician-  
855 rated scale ranked from 1-very much improved to 7-very much worse. **D)** Quality of Life  
856 Enjoyment and Satisfaction Questionnaire – Short Form scores (Q-LES-SF).




857



858



859




860

861

862 **Supplementary Figure S5. Paired associative stimulation.**

863 Group data (estimated marginal means  $\pm$  bootstrapped 95% confidence intervals) showing the  
864 time course of changes in the amplitude of motor evoked potentials (MEPs) immediately  
865 after the PAS conditioning stimulus. Post-PAS MEP amplitudes were normalized to pre-PAS  
866 amplitudes for each participant. **A)** MEP amplitude changes at baseline, prior to the course of  
867 tRNS. **B)** MEP amplitude changes following the 4-week sham-controlled phase.




868



869 **Supplementary Figure S6. Correlation between mood and neuroplasticity.**

870 There was no association between percent change in motor evoked potentials (MEPs)  
871 following paired associative stimulation (PAS) and percent change in mood scores over the  
872 course of the sham-controlled phase ( $r = -0.02, p = 0.905$ ).



873

874